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Abstract
Electrical storm (ES) is a clinical condition characterized 
by three or more ventricular arrhythmia episodes 
leading to appropriate implantable cardioverter-
defibrillator (ICD) therapies in a 24 h period. Mostly, 
arrhythmias responsible of ES are multiple morphologies 
of monomorphic ventricular tachycardia (VT), but poly-
morphic VT and ventricular fibrillation can also result 
in ES. Clinical presentation is very dramatic in most 
cases, strictly related to the cardiac disease that may 
worsen electrical and hemodynamic decompensation. 
Therefore ES management is challenging in the majority 
of cases and a high mortality is the rule both in the 
acute and in the long-term phases. Different underlying 
cardiomyopathies provide significant clues into the 
mechanism of ES, which can arise in the setting of 
structural arrhythmogenic cardiomyopathies or rarely in 
patients with inherited arrhythmic syndrome, impacting 
on pharmacological treatment, on ICD programming, 
and on the opportunity to apply strategies of catheter 
ablation. This latter has become a pivotal form of 
treatment due to its high efficacy in modifying the 
arrhythmogenic substrate and in achieving rhythm 
stability, aiming at reducing recurrences of ventricular 
arrhythmia and at improving overall survival. In this 
review, the most relevant epidemiological and clinical 
aspects of ES, with regard to the acute and long-term 
follow-up implications, were evaluated, focusing on 
these novel therapeutic strategies of treatment.
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Core tip: Electrical storm is an increasingly common and 
life-threatening syndrome. The proper management of 
this arrhythmic emergency is related to a comprehensive 
assessment of each case. In this review we report 
all the essential aspects regarding the clinical and 
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diagnostic evaluation, pharmacological treatment and, 
with special emphasis, catheter ablation approaches.
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INTRODUCTION
Electrical storm (ES), also referred as arrhythmic storm, 
refers to a clinical condition characterized by 3 or more 
arrhythmia episodes of ventricular tachycardia (VT) 
or ventricular fibrillation (VF) leading to implantable 
cardioverter-defibrillator (ICD) therapies (Antitachycar-
dia Pacing, ATP, or Direct Current shock, DC-shock), 
occurring over a single 24 h period[1]. ES represents an 
arrhythmic emergency that often affects patients at high 
risk of sudden cardiac death who previously underwent 
ICD implantation. In this setting ICD correctly interrupts 
VT/VF episodes; however ventricular arrhythmias, 
in terms of arrhythmogenic substrate, represent the 
gradual evolution of the underlying structural heart 
disease. In this review, we assess the most relevant 
epidemiological and clinical aspects of ES, with regard to 
the acute and long-term follow-up implications, focusing 
on novel therapeutic strategies of treatment.
CLINICAL CHARACTERIZATION
The term ES was introduced in the 1990s to describe 
an instability condition, highly malignant, characterized 
by repetitive episodes of ventricular arrhythmias[2]. 
Nowadays, ES implies several appropriate ICD inter-
ventions aimed at terminating the arrhythmic episodes.
ES has been reported in 10%-40% of patients in 
secondary prevention whereas the incidence of ES is 
lower (3.5%-4%) in primary prevention[3-16]. However, 
the correct incidence of ES is uncertain due to several 
confounding factors such as population considered, 
type of cardiomyopathy, pharmacological therapy 
undertaken and other variables. In addition, most of the 
studies concerning ES incidence were retrospective thus 
including only the patients who survived the arrhythmic 
event. 
ES mainly affects patients with advanced dilated 
cardiomyopathy, both ischemic and non-ischemic, 
representing the gradual evolution of the underlying 
arrhythmic substrate; however, ES may affect patients 
with different types of structural heart disease, such 
as valvular or congenital heart disease, as well as 
patients without structural heart disease (i.e., Brugada 
syndrome)[17]. 
The most significant predictors of ES are severe 
reduction of left ventricle (LV) function, advanced age 
and previous VT/VF episodes[8,10,11,13,18,19]. Monomorphic 
ventricular tachycardia is the most common arrhy-
thmia documented in ES patients. VT episodes, hemo-
dynamically unstable and interrupted with ATP or 
DC-shock, are the rule, with evidence of multiple VT 
morphologies[20]. Anyway, clinical presentation of ES is 
variable[9]. 
Less commonly, ES has been recorded in patients 
in whom premature ventricular complexes are the 
trigger of VT/VF both in acute myocardial infarction and 
in absence of structural heart disease[16,21]. The latter 
are often patients with “primitive ventricular fibrillation”, 
in whom the trigger of the arrhythmia has not been 
documented, presenting with multiple VF episodes after 
ICD implantation, mostly refractory to pharmacological 
therapy. Therefore, in this setting, the identification of ES 
triggers may be of interest in preventing VT/VF episodes, 
particularly in case of electrolyte disorder[9,14]. The role 
of adrenergic system in maintaining ES is of special 
interest as well; in terms of acute event treatment[7,16]. 
Adrenergic activation seems to play a key role in patients 
with arrhythmogenic right ventricular cardiomyopathy/
dysplasia due to the well known arrhythmic sensitivity to 
adrenergic stimulation; although in the majority of these 
patients the trigger is unkown[22].
ACUTE PRESENTATION, PROGNOSTIC 
RELEVANCE
ES is an arrhythmic emergency related to recurrent 
consecutive episodes of ventricular arrhythmia, with low 
likelihood of spontaneous termination. 
The clinical scenario of ES is the result of a com-
bination of various factors: in patients with structural 
heart disease affected by chronic heart failure, ES causes 
worsening of heart failure with high risk of pulmonary 
edema/cardiogenic shock. These events are much more 
frequent and severe, less stable the arrhythmic condition 
and the functional status are. ICD therapies even if allow 
arrhythmic episodes termination and prevent sudden 
cardiac death, do not play any role in stabilizing the 
clinical scenario. Moreover, the continuous intervention 
of ICD, implies unfavorable hemodynamic effects[3], 
also resulting in psychological distress, adrenergic 
hyperactivity, and patient discomfort[22,23].
No reproducible data on acute mortality in ES are 
available. It should be reminded that acute mortality 
represents a common cause of death in patients with 
severe structural heart disease, in most of cases as 
cardiogenic shock or electromechanical dissociation in 
the setting of unmanageable arrhythmias[3]. Literature 
data show that patients with ES present an increased 
risk of sudden arrhythmic or cardiac death in the mid-
term follow up[8-10,16,24]; furthermore, these findings 
were not confirmed just in few papers[7,13]. The MADIT II 
trial showed that patients with VT episodes interrupted 
by ICD have a significantly higher risk of sudden and 
non-sudden cardiac death. Moreover, patients who have 
survived ventricular arrhythmias have an increased risk 
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of worsening heart failure and of mortality related to 
it[25]. Specifically, in the MADIT II trial, Sesselberg et al[11] 
have shown that ES is the most important independent 
predictor of mid-term cardiac death (increased risk of 
7-fold), resulting particularly significant in the first 3 mo 
after ES (increasing risk of 18-fold). The results of SCD-
HeFT trial are comparable, in addition, Poole et al[26] 
observed that not only appropriate shocks - directly 
related with arrhythmic events - but also inappropriate 
shocks impact on an increased mortality. More speci-
fically the authors reported a significant increase of 
death in patients with appropriate (HR = 5.68; P < 
0.001) and inappropriate shocks (HR = 1.98; P = 0.002). 
In particular, multiple shocks were associated with a 
8-fold risk of death (HR = 8.23; P < 0.001).
These findings support the hypothesis that the 
recurrence of frequent arrhythmic events (and even 
more ES) strongly impacts on the evolution of patients’ 
clinical history, particularly by worsening the cardiac 
function. In this setting multiple shocks could have 
their own etiopathogenetic role related to repeated 
myocardial injury.
DIAGNOSIS AND CLINICAL 
MANAGEMENT
Patients with ES require a diagnostic evaluation of their 
structural heart disease, the type of arrhythmia and 
the presence of clinical triggers. The most common 
triggering factors are acute myocardial ischemia, 
electrolytic disorders and adverse drug effects. Identi-
fication of triggers is a key point: sometimes it allows 
the suppression of arrhythmias through simple thera-
peutic interventions, such as in case of hypokalaemia. 
Acute myocardial ischemia must be accurately identified 
and excluded through clinical and non-invasive diag-
nostic parameters. However, in most patients with 
coronary artery disease and previous history of myo-
cardial infarction presenting with ES, myocardial ische-
mia is just a secondary effect of the arrhythmias. 
Myocardial ischemia should therefore be interpreted and 
consequently treated with the aid of pharmacological 
and/or interventional therapies in the presence of acute 
coronary syndrome. In the majority of cases, however, 
ES represents the evolution of an arrhythmogenic sub-
strate in patients with previous VT/VF episodes.
Therapeutic interventions first depend on the 
arrhythmic pattern and on the hemodynamic stability of 
patients. ICD interrogation is the preliminary diagnostic 
step to evaluate the appropriateness of shock delivery 
and arrhythmic parameters (heart rate, electrogram 
analysis, trigger). ICD reprogramming is mandatory 
in order to both limit ICD shock delivery and attempt 
VT/VF interruption with antitachycardia pacing[27,28]. 
The accuracy of the diagnosis of ventricular arrhythmia 
may only occasionally show interpretative troubles in 
single-chamber ICD recipients in whom the comparison 
between basal and arrhythmic electrograms should be 
557 September 26, 2015|Volume 7|Issue 9|WJC|www.wjgnet.com
carried out carefully privileging reading from multiple 
recording channels.
ES patients require hospitalization. A continuous 
ECG and vital signs monitoring must be performed 
in the Coronary Intensive Care Unit or in a dedicated 
Emergency Arrhythmia Unit. During the evaluation 
phase, the possibility to document and characterize 
different morphologies of VT responsible for the clinical 
scenario is relevant, also with regard to a possible 
ablative treatment[20].
Hemodynamic and metabolic evaluations are needed 
in order to perform urgent interventions through intra-
venous therapies, such as inotropic agents or hydro-
electrolytic infusion.
In the acute setting, prevention of arrhythmic 
recurrence should be as efficient as possible, by means 
of: (1) amiodarone is the first choice drug, unless 
contraindicated (presence of hyperthyroidism, long 
QT interval)[29]; (2) beta-blocker administration plays 
an important role because of its antiarrhythmic and 
antiadrenergic effect. Beta-blockers administration 
should be limited in patients with labile hemodynamic 
compensation or severe reduction of LV function; (3) 
lidocaina and azimilide are second choice drugs, useful 
in case of contraindications to previous medications[14,30]; 
(4) verapamile should be used as drug of choice 
in case of premature ventricular beats originating 
from His-Purkinje system; and (5) finally, atrial or 
sequential atrio-(bi)ventricular pacing are useful to avoid 
bradycardia[31,32].
Sedation is pivotal to stabilize patients with ES, but 
hemodynamic and/or respiratory instability can limit 
the use of sedation drugs, such as benzodiazepine. In 
these cases mechanical ventilation with oro-tracheal 
intubation are absolutely required in refractory forms of 
ES. In some cases mechanical ventilation allows safer 
drugs administration otherwise not tolerated.
ROLE OF CATHETER ABLATION
The role of catheter ablation (CA) in patients with VT 
is becoming more and more relevant, as a definite 
treatment of multiple forms of arrhythmias and a 
complementary intervention in cases of high electrical 
instability, thus improving prognosis and quality of 
life in patients with advanced forms of heart disease. 
This observation creates the rationale to investigate 
the possibility to apply CA in patients with frequently 
recurring ventricular arrhythmias and ES[33].
Preliminary reports regarding the role of CA in the 
treatment of ES are limited to patients with specific 
clinical characteristics and/or small case series. Silva et 
al[34] reported a success rate of 80% in an ES population 
with recurrent hemodynamic stable VT; Schreieck 
et al[35] reported acute success in most of cases of a 
selected population undergoing CA of hemodynamic 
unstable arrhythmias guided by substrate mapping. 
Also Bänsch et al[16] described CA in patients with acute 
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The ability to assess the feasibility and effectiveness 
of CA in a wider ES population arises from more 
myocardial infarction and ES in whom VF was triggered 
by premature ventricular contractions, targeted by CA. 
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Figure 1  Kaplan-Meier survival analysis after catheter ablation of electrical storm. Class A indicates catheter ablation success, defined as suppression of 
each ventricular tachycardia (VT) morphology; Class B indicates partial success, defined as suppression of each clinical VT; Class C indicates failure, defined as 
persistence of one or more clinical VT (reprinted from Carbucicchio et al[20]).
A B C
Figure 2  Modern approach of mapping and ablation for the treatment of electrical storm: High-density electroanatomical mapping of the left ventricle 
using CARTOSOUND contact-force technology (Biosense Webster, Diamond Bar, CA, United States). A: Two distinct peri-valvular scars, in the mitro-
aortic continuity and below the mitral annulus, in the setting of idiopathic cardiomyopathy are visualized. Scars are characterized by dense scar (abnormal bipolar 
electrograms < 0.20 mV), surrounded by a border zone (0.20-1.20 mV) in which late potentials, are tagged (dark and light blue dots); B: Radiofrequency ablation lines 
are dragged for dechanneling and isolation of all proarhythmic sites; C: Intracardiac echocardiography imaging is aiming at substrate characterization and correct 
positioning of the catheter during mapping and ablation.
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to achieve long-term rhythm stabilization and to 
prevent heart failure. The possibility to modify the 
arrhythmic substrate by CA in an early phase, thus 
preventing critical situations deriving from repetitive ICD 
interventions, looks promising, but necessitates further 
corroborations.
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